Normosol-R
Phase 1Small molecule
Normosol-R is one of 70 small molecule programs targeting Toxicity. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
223 competitors in Toxicity
#DrugCompanyPhaseTrials
1Mucosta
OtsukaPhase 3
Paracetamol
GSKPhase 3
Curcumin
Merck & Co.Phase 3
Cysteine Hydrochloride
NovartisPreclinical
Afinitor
NovartisPreclinical
Imfinzi
AstraZenecaPreclinical
Cellcept
NovartisPreclinical
Yervoy
Bristol-Myers SquibbPreclinical
Alecensa
RochePreclinical
Ritalin
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Normosol-R. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- JJohns Hopkins University